Dr. Sims is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
705 Riley Hospital Dr
Indianapolis, IN 46202Phone+1 317-944-3889Fax+1 317-944-3882
Summary
- Dr. Emily K. Sims MD, MS is a physician scientist specializing in pediatric endocrinology, with a long-term goal of addressing clinically relevant problems in diabetes utilizing molecular discovery. Her research focus revolves around the investigation of molecular mechanisms contributing to β cell dysfunction and the development of diabetes, the identification and verification of circulating biomarkers of β cell dysfunction, and clinical studies identifying and targeting β cell dysfunction in T1D. She hopes to ultimately utilize knowledge gained for development of biomarkers and β cell-targeted therapeutics that allow for a more tailored approach to treatment of patients with or at-risk for diabetes.
Education & Training
- Indiana University School of MedicineFellowship, Pediatric Endocrinology, 2013
- University of Alabama School of MedicineClass of 2007
Certifications & Licensure
- IN State Medical License 2010 - 2025
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Endocrinology
Publications & Presentations
PubMed
- Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab.Alfonso Galderisi, Emily K Sims, Carmella Evans-Molina, Alessandra Petrelli, David Cuthbertson
Diabetologia. 2024-11-19 - Beta cell extracellular vesicle PD-L1 as a novel regulator of CD8T cell activity and biomarker during the evolution of type 1 diabetes.Chaitra Rao, Daniel T Cater, Saptarshi Roy, Jerry Xu, Andre G De Oliveira
Diabetologia. 2024-11-07 - Beta cell extracellular vesicle PD-L1 as a novel regulator of CD8+ T cell activity and biomarker during the evolution of Type 1 Diabetes.Chaitra Rao, Daniel T Cater, Saptarshi Roy, Jerry Xu, Andre De G Olivera
Biorxiv. 2024-09-19
Press Mentions
- Type 1 Diabetes: Recent Wins and Ongoing Challenges on the Road to a CureMay 24th, 2023
- IU Research Contributes to First FDA-approved Drug to Delay Onset of Type 1 DiabetesNovember 21st, 2022
- FDA Approves First-Ever Agent to Delay Type 1 Diabetes OnsetNovember 18th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: